Results 211 to 220 of about 214,804 (267)
Some of the next articles are maybe not open access.
Contact Dermatitis, 1996
92 children (45 girls, 47 boys), mean age 9.3 years (3‐14.75), were referred to the Contact Dermatitis Investigation Unit, Belvidere Hospital, Glasgow, for patch testing during the period 1979–93 for the investigation of allergic contact dermatitis (ACD). The diagnoses at the time of referral were atopic dermatitis (45).
G I, Stables, A, Forsyth, R S, Lever
openaire +2 more sources
92 children (45 girls, 47 boys), mean age 9.3 years (3‐14.75), were referred to the Contact Dermatitis Investigation Unit, Belvidere Hospital, Glasgow, for patch testing during the period 1979–93 for the investigation of allergic contact dermatitis (ACD). The diagnoses at the time of referral were atopic dermatitis (45).
G I, Stables, A, Forsyth, R S, Lever
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1967
Patch testing consists of the application of substances to the skin for the purpose of detecting specific hypersensitivity. It serves as an admirable diagnostic tool in the clinical study of patients who have inflammatory dermatitic reactions of an allergic nature.
openaire +2 more sources
Patch testing consists of the application of substances to the skin for the purpose of detecting specific hypersensitivity. It serves as an admirable diagnostic tool in the clinical study of patients who have inflammatory dermatitic reactions of an allergic nature.
openaire +2 more sources
Clinical Reviews in Allergy & Immunology, 2018
Dermatitis is one of the most common illnesses encountered by healthcare providers and the causes are numerous. Contact dermatitis is the form of dermatitis resulting from contact with the environment, and it may be either irritant or allergic in nature.
Betty A, Uyesugi, Michael P, Sheehan
openaire +2 more sources
Dermatitis is one of the most common illnesses encountered by healthcare providers and the causes are numerous. Contact dermatitis is the form of dermatitis resulting from contact with the environment, and it may be either irritant or allergic in nature.
Betty A, Uyesugi, Michael P, Sheehan
openaire +2 more sources
Prognostic patch testing: The other kind of patch test
American Journal of Contact Dermatitis, 1998Prognostic patch testing differs from diagnostic patch testing. Clinicians routinely perform diagnostic patch testing, but prognotic patch testing is the province of corporate research and development departments and, in the United States, contract laboratories.
openaire +2 more sources
Contact Dermatitis, 1985
Routine path testing with a series of 6 industrial biocides containing methylene‐bis‐thiocyanate (Cytoc 3522®), benzosothizolin‐3‐one (BIT), chlorocresol (Preventol CMK®), 2‐n‐octyl‐4‐isothiazolin‐3‐one (Kathon 863®), polyhdroxymethylene monobenzylether (Preventol D2®) or 1,3,5‐tris (hydroxy‐ethyl) hexahydrotrizine (Grotan BK®) was carried out in 6 ...
K E, Andersen, N K, Veien
openaire +2 more sources
Routine path testing with a series of 6 industrial biocides containing methylene‐bis‐thiocyanate (Cytoc 3522®), benzosothizolin‐3‐one (BIT), chlorocresol (Preventol CMK®), 2‐n‐octyl‐4‐isothiazolin‐3‐one (Kathon 863®), polyhdroxymethylene monobenzylether (Preventol D2®) or 1,3,5‐tris (hydroxy‐ethyl) hexahydrotrizine (Grotan BK®) was carried out in 6 ...
K E, Andersen, N K, Veien
openaire +2 more sources
Patch testing with methyldibromoglutaronitrile
American Journal of Contact Dermatitis, 2000The combination of methyldibromoglutaronitrile (MDBGN) and phenoxyethanol (PE) is widely used as a preservative in body care products. Sensitization rates to MDBGN have increased parallel to its increasing use in cosmetics, skin care products, and moist toilet paper since the early 1990s, whereas PE is obviously not a sensitizer.
J, Geier +3 more
openaire +2 more sources
Dermatitis®, 2013
Adverse drug reactions occur commonly and primarily manifest in a myriad of cutaneous eruptions. The use of drug patch testing in the diagnosis of specific drug eruptions is increasing; however, a standardized approach to this methodology is currently lacking.
Marcella Rita, Aquino +2 more
openaire +2 more sources
Adverse drug reactions occur commonly and primarily manifest in a myriad of cutaneous eruptions. The use of drug patch testing in the diagnosis of specific drug eruptions is increasing; however, a standardized approach to this methodology is currently lacking.
Marcella Rita, Aquino +2 more
openaire +2 more sources
Current Opinion in Otolaryngology & Head & Neck Surgery, 2010
Patch testing has rapidly become an important clinical allergy tool, but is underutilized in the evaluation of complex patients, especially when these patients have skin disorders and respiratory allergies, food allergies, or eosinophilic enteritis.
openaire +2 more sources
Patch testing has rapidly become an important clinical allergy tool, but is underutilized in the evaluation of complex patients, especially when these patients have skin disorders and respiratory allergies, food allergies, or eosinophilic enteritis.
openaire +2 more sources
Bioengineering and the patch test
Contact Dermatitis, 1988Several non‐invasive techniques based on different physical principles have been developed to investigate skin function and have been used for patch test assessment. In the present paper, the advantages and the defects of these methods are described in the light of the more recent data available in literature.
E, Berardesca, H I, Maibach
openaire +2 more sources
Archives of Dermatology, 1995
When I editorialized on patch testing for corticosteroid allergy, budesonide was unavailable in the United States. 1 Late in 1994, the US Food and Drug Administration approved a new nasal inhaler known as Rhinocort, which is budesonide made available in a metered-dose apparatus. The 7-g canister contains 200 metered doses, each containing approximately
openaire +2 more sources
When I editorialized on patch testing for corticosteroid allergy, budesonide was unavailable in the United States. 1 Late in 1994, the US Food and Drug Administration approved a new nasal inhaler known as Rhinocort, which is budesonide made available in a metered-dose apparatus. The 7-g canister contains 200 metered doses, each containing approximately
openaire +2 more sources